secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zomedica Corp. (ZOMDF)
CIK:        0001684144
Form:       8-K
Filed at:   2025-08-06T23:59:59+00:00
Accession:  0001654954-25-009136
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zomedica Q2 revenue up 14% to $7M; Diagnostics segment jumps 86%
----------------------------------------------------------------

- Revenue $7.0M, up 14% YoY; gross margin 67%, consistent with prior period.
- Diagnostics segment revenue $0.8M (+86%), driven by TRUFORMA platform adoption.
- Net loss $7.4M vs $23.9M (including $16M impairment) in Q2 2024; Adj. EBITDA loss $5.5M.
- Operating expenses down $0.7M excluding impairment; liquidity $59.1M.
- Record 18th consecutive quarter of YoY revenue growth; consumable sales up 21%.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/0001654954-25-009136-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1684144/000165495425009136/zom_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-25-009136

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer